Tao Guo

Effect of prior adjuvant radiotherapy on immunotherapy outcomes in recurrent endometrial cancer

This study aimed to investigate the impact of adjuvant external beam radiotherapy (EBRT) following initial surgery on the efficacy of immunotherapy in patients with recurrent endometrial cancer. This is a single-institution retrospective cohort study. Patients who underwent initial surgery for endometrial cancer and received immunotherapy for recurrence between January 2020 and December 2023 were recruited. Patients who received post-operative EBRT were assigned to the EBRT group. Patients who did not undergo EBRT or who received brachytherapy without EBRT were assigned to the control group. Progression-free survival was used as the end point. Kaplan-Meier curves were used for comparing progression-free survival. The multi-variate analysis was performed using the Cox proportional hazards regression model. A total of 91 patients were included in the analysis; 33 had a history of EBRT, while 58 had not received prior EBRT. In Kaplan-Meier curves, patients who did not receive EBRT showed a numerically lower risk of disease progression (HR 0.47, 95% CI 0.25 to 0.90, p = .010). In multi-variate analysis, EBRT (HR 5.28, 95% CI 1.54 to 22.06) and proficient mismatch repair/micro-satellite instability-low/micro-satellite stable status (HR 3.15, 95% CI 1.19 to 8.90) were risk factors for disease progression during immunotherapy. In patients with recurrent endometrial cancer who received immunotherapy, the therapeutic efficacy may be compromised by prior post-operative adjuvant EBRT.

Cotyledonoid Dissecting Leiomyoma of the Uterus: A Benign Uterine Tumor That Resembles Malignancy

A Rare Case of Typical and Unforgettable Cervical Malignant Melanoma